Cargando…

MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study

BACKGROUND: Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) regulates immune/inflammation response and kidney injury, indicating that it might participate in the lupus nephritis (LN) pathology. The present study sought to investigate the utility of MALT1 serving as an indi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Min, Huang, Li, Peng, Liping, Yang, Yameng, Mao, Jing, Zhu, Ning, Wu, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469135/
https://www.ncbi.nlm.nih.gov/pubmed/36111027
http://dx.doi.org/10.21037/atm-22-3442
_version_ 1784788572968058880
author Wang, Min
Huang, Li
Peng, Liping
Yang, Yameng
Mao, Jing
Zhu, Ning
Wu, Bin
author_facet Wang, Min
Huang, Li
Peng, Liping
Yang, Yameng
Mao, Jing
Zhu, Ning
Wu, Bin
author_sort Wang, Min
collection PubMed
description BACKGROUND: Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) regulates immune/inflammation response and kidney injury, indicating that it might participate in the lupus nephritis (LN) pathology. The present study sought to investigate the utility of MALT1 serving as an indicator of severity and inflammation biomarker in LN. METHODS: In total, 30 LN patients and 30 non-LN systemic lupus erythematosus (SLE) patients were recruited, and blood MALT1 expression was detected using reverse transcription-quantitative polymerase. Besides, the SLE disease activity index was calculated for all subjects to assess disease activity. RESULTS: MALT1 was more increased in LN patients than non-LN SLE patients {2.26 [interquartile range (IQR): 1.38–3.54] vs. 1.04 (IQR, 0.60–1.62); P<0.001}. Additionally, the multivariate logistic regression model analysis indicated that higher MALT1 [odds ratio (OR): 3.097, 95% CI: 1.292–7.425, P=0.011] and higher serum creatinine (Scr) (OR: 1.055, 95% CI: 1.012–1.099, P=0.011) were independently related to an elevated risk of LN. The MALT1 and Scr-based nomogram exhibited a good value in estimating LN risk with an area under the curve (AUC) of 0.873 (95%CI: 0.787–0.960). MALT1 was highest in LN patients with class IV (accompanied by V or not), followed by class V and class III (accompanied by V or not) patients, and lowest in class II patients (P=0.046). MALT1 was positively linked to the LN activity index (r(s)=0.370, P=0.044); however, while it was positively associated with the LN chronicity index, the level did not reach statistical significance (r(s)=0.341, P=0.066). MALT1 was positively linked to 24 h proteinuria (r(s)=0.473, P=0.008), Scr (r(s)=0.378, P=0.039), and C-reactive protein (CRP) (r(s)=0.410, P=0.025) in LN patients. CONCLUSIONS: MALT1 might serve as a useful biomarker for estimating the disease risk in LN patients; however, future large-sample size studies need to be conducted to validate our findings.
format Online
Article
Text
id pubmed-9469135
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-94691352022-09-14 MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study Wang, Min Huang, Li Peng, Liping Yang, Yameng Mao, Jing Zhu, Ning Wu, Bin Ann Transl Med Original Article BACKGROUND: Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) regulates immune/inflammation response and kidney injury, indicating that it might participate in the lupus nephritis (LN) pathology. The present study sought to investigate the utility of MALT1 serving as an indicator of severity and inflammation biomarker in LN. METHODS: In total, 30 LN patients and 30 non-LN systemic lupus erythematosus (SLE) patients were recruited, and blood MALT1 expression was detected using reverse transcription-quantitative polymerase. Besides, the SLE disease activity index was calculated for all subjects to assess disease activity. RESULTS: MALT1 was more increased in LN patients than non-LN SLE patients {2.26 [interquartile range (IQR): 1.38–3.54] vs. 1.04 (IQR, 0.60–1.62); P<0.001}. Additionally, the multivariate logistic regression model analysis indicated that higher MALT1 [odds ratio (OR): 3.097, 95% CI: 1.292–7.425, P=0.011] and higher serum creatinine (Scr) (OR: 1.055, 95% CI: 1.012–1.099, P=0.011) were independently related to an elevated risk of LN. The MALT1 and Scr-based nomogram exhibited a good value in estimating LN risk with an area under the curve (AUC) of 0.873 (95%CI: 0.787–0.960). MALT1 was highest in LN patients with class IV (accompanied by V or not), followed by class V and class III (accompanied by V or not) patients, and lowest in class II patients (P=0.046). MALT1 was positively linked to the LN activity index (r(s)=0.370, P=0.044); however, while it was positively associated with the LN chronicity index, the level did not reach statistical significance (r(s)=0.341, P=0.066). MALT1 was positively linked to 24 h proteinuria (r(s)=0.473, P=0.008), Scr (r(s)=0.378, P=0.039), and C-reactive protein (CRP) (r(s)=0.410, P=0.025) in LN patients. CONCLUSIONS: MALT1 might serve as a useful biomarker for estimating the disease risk in LN patients; however, future large-sample size studies need to be conducted to validate our findings. AME Publishing Company 2022-08 /pmc/articles/PMC9469135/ /pubmed/36111027 http://dx.doi.org/10.21037/atm-22-3442 Text en 2022 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wang, Min
Huang, Li
Peng, Liping
Yang, Yameng
Mao, Jing
Zhu, Ning
Wu, Bin
MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study
title MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study
title_full MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study
title_fullStr MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study
title_full_unstemmed MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study
title_short MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study
title_sort malt1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469135/
https://www.ncbi.nlm.nih.gov/pubmed/36111027
http://dx.doi.org/10.21037/atm-22-3442
work_keys_str_mv AT wangmin malt1servesasabiomarkerforestimatingdiseaseriskoflupusnephritisaprospectivecasecontrolstudy
AT huangli malt1servesasabiomarkerforestimatingdiseaseriskoflupusnephritisaprospectivecasecontrolstudy
AT pengliping malt1servesasabiomarkerforestimatingdiseaseriskoflupusnephritisaprospectivecasecontrolstudy
AT yangyameng malt1servesasabiomarkerforestimatingdiseaseriskoflupusnephritisaprospectivecasecontrolstudy
AT maojing malt1servesasabiomarkerforestimatingdiseaseriskoflupusnephritisaprospectivecasecontrolstudy
AT zhuning malt1servesasabiomarkerforestimatingdiseaseriskoflupusnephritisaprospectivecasecontrolstudy
AT wubin malt1servesasabiomarkerforestimatingdiseaseriskoflupusnephritisaprospectivecasecontrolstudy